Regardless of primary organ origin, metastatic MSI cancers tend to respond to the currently popular PD1/PD-L1 immune checkpoint inhibitors, whereas MSS cancers generally do not respond well [9, 10]. This evidence concerns the gene PDCD1 and cancer.